Akademik Veri Yönetim Sistemi
Diseases of the Colon and Rectum, cilt.65, sa.5, ss.735-741, 2022 (SCI-Expanded)
BACKGROUND: As a chronic condition, pilonidal disease affects a young population, and recovery after the surgical procedures performed to treat this condition require time off from work. Therefore, the search for an ideal treatment is still ongoing. OBJECTIVE: The aim of this study was to compare early and late results of 2 minimally invasive treatment options used to treat pilonidal disease. DESIGN: This study was designed as a parallel group randomized clinical trial. SETTINGS: This study took place at an outpatient clinic in Turkey. PATIENTS: Patients with pilonidal disease were evaluated for the study and were enrolled if they met the inclusion criteria and gave informed consent. INTERVENTIONS: Patients in the platelet-rich plasma group were treated using curettage + platelet-rich plasma gel. Patients in the phenol group were treated by using curettage + crystallized phenol. MAIN OUTCOME MEASURES: The primary study end point was the time to achieve healing; the secondary outcome was recurrence rate. RESULTS: In the platelet-rich plasma group, 96% of patients achieved healing after 1 application. In the phenol group, only 53% patients achieved healing after 1 application. The median healing time was shorter in the platelet-rich plasma group: 6 (4–14) vs 10 (5–42) days (p < 0.001). The mean difference in healing was 5.8 days (95% CI, 4.27–7.38). After a mean follow-up of 43.1 months, there was a 4% recurrence rate in the platelet-rich plasma group in comparison with a 12% recurrence rate in the phenol group (95% CI, 0.024–0.251). LIMITATIONS: Despite the randomized prospective nature of the study, neither the patients nor the investigators were blinded. CONCLUSIONS: The curettage + platelet-rich plasma method can be safely applied with an improved healing time, low recurrence rate, and minimal time off work.